Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
1672 participants
INTERVENTIONAL
1999-09-30
2001-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Design: Multicenter, randomized, double blind Phase II study to compare a 50 mg dose of CDB-2914 to a 0.75 mg bid dose of levonorgestrel as emergency contraception
Subjects are randomized to receive a one-time treatment with either one dose of 50 mg CDB-2914 (followed 12 hours later by a placebo) or 2 doses of 0.75 mg of levonorgestrel with follow-up visits at 5-7 days after expected onset of menses and another visit at 12-14 days after expected onset of menses (if needed)
The primary aim is to evaluate the efficacy of CDB-2914 used by subjects as an emergency postcoital contraceptive in comparison to a group of subjects receiving levonorgestrel.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Design: Multicenter, randomized, double blind Phase II study to compare a 50 mg dose of CDB-2914 to a 0.75 mg bid dose of levonorgestrel as emergency contraception
Duration: A one-time treatment with either CDB-2914 or levonorgestrel with follow-up visits at 5-7 days after expected onset of menses and another visit at 12-14 days after expected onset of menses (if needed)
Treatment: A one-time treatment with one of the following:
* Two doses of 0.75 mg of levonorgestrel to be taken 12 hours apart
* One dose of 50 mg CDB-2914 and a second placebo dose to be taken 12 hours later
Study Sites: Multicenter study in the United States
Subjects: Women of reproductive age (at least 18 years) at risk of pregnancy within 72 hours of unprotected coitus
Sample Size: Approximately 811 women will be enrolled in each treatment group to obtain 1540 evaluable subjects
Outcome Evaluations
Primary: To evaluate the efficacy of CDB-2914 used by subjects as an emergency postcoital contraceptive in comparison to a group of subjects receiving levonorgestrel.
Secondary: To compare the tolerability (as measured by vomiting and nausea) of CDB-2914 used by subjects as an emergency postcoital contraceptive with that of a group of subjects receiving levonorgestrel.
Safety/Other: To assess the frequency and intensity of adverse events and the effects on the menstrual cycle of subjects administered CDB-2914 in comparison to subjects given levonorgestrel.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CDB-2914
levonorgestrel
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Give voluntary, written informed consent, and agree to observe all study requirements;
* Request emergency contraception within 72 hours (3 days) after unprotected coitus, as defined by lack of contraceptive use, or condom breakage (including condoms lubricated with spermicide) or other barrier contraceptive method failure;
* Reports that all acts of unprotected coitus during the current cycle are within 72 hours prior to enrollment;
* Willing to abstain from further acts of unprotected intercourse during that cycle;
* History of regular menstrual cycles (mean length of 24-42 days with intra-individual variation of ±5 days);
* At least one normal menstrual cycle (2 menses) post delivery or abortion;
* If subject recently discontinued hormonal contraception, one normal menstrual cycle (2 menses) must have been completed before entry in the study
* For women with a recent history of Depo Provera use, the most recent injection must be at least 3 months before study entry and the subject must have had at least one normal menstrual cycle (2 menses);
* Available for follow-up for at least the next four weeks.
* nausea and vomiting within the previous two weeks;
* impaired hypothalamic-pituitary-adrenal reserve or oral glucocorticoid replacement therapy in the last year.
Subjects cannot be currently enrolled in any other investigational trial or re-enrolled in this study.
Exclusion Criteria
* pregnant or breast-feeding within the past two months;
* use of hormonal methods of contraception during the current or previous two cycles;
* current user of IUD;
* tubal ligation;
* partners with history of vasectomy;
* unsure about the date of the last menstrual period (+3 days);
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
University of Pittsburgh
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Diana Blithe, PhD
Role: PRINCIPAL_INVESTIGATOR
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
California Family Health Council
Los Angeles, California, United States
University of Colorado
Denver, Colorado, United States
New York University
New York, New York, United States
University of Cincinnati
Cincinnati, Ohio, United States
University of Pittsburgh
Pittsburgh, Pennsylvania, United States
Eastern Virginia Medical School
Norfolk, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Creinin MD, Schlaff W, Archer DF, Wan L, Frezieres R, Thomas M, Rosenberg M, Higgins J. Progesterone receptor modulator for emergency contraception: a randomized controlled trial. Obstet Gynecol. 2006 Nov;108(5):1089-97. doi: 10.1097/01.AOG.0000239440.02284.45.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
N01-HD-9-3298
Identifier Type: -
Identifier Source: secondary_id
CCN002
Identifier Type: -
Identifier Source: org_study_id